Laurent Humeau

Laurent Humeau has over twenty years of experience in the biotechnology industry, focusing on advancing cutting-edge technologies into clinical applications.

He has provided scientific leadership across various stages from discovery to early clinical programs, including managing patent portfolios and relationships with investors, partners, vendors, and regulatory bodies.

Laurent Humeau possesses extensive expertise in leading diverse groups in disciplines like gene and cell therapies for infectious, genetic, and ocular disorders, cancer immunotherapies, and vaccine development.

He played a crucial role in developing a groundbreaking autologous T cell immunotherapy for HIV treatment and has experience with different viral and non-viral delivery systems for various diseases.

Known for his strong project management skills and problem-solving abilities, he has a track record of successfully managing complex projects and retaining key talent.

Laurent Humeau's educational background includes studying at prestigious institutions such as University Paris VI, University Denis Diderot, and Université Denis Diderot in France.

Currently, he serves as the Chief Scientific Officer at Inovio Pharmaceuticals Inc. and has held various executive positions in research, development, and clinical roles in renowned organizations like VIRxSYS Corporation and Intrexon Corporation.